ReviewFrontiers in oncology2025
Unveiling the impact of lipid metabolism on triple-negative breast cancer growth and treatment options.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Identification and functional validation of lipid droplet-associated prognostic biomarkers in breast cancer via integrative multi-omics and machine learning approaches.International journal of clinical oncology · 2026Article
- Article
- Review
- Lipogenesis-driven EGFR palmitoylation enables metastatic immune evasion in triple-negative breast cancer.bioRxiv : the preprint server for biology · 2026Article
- Subtype-Consistent Upregulation of Ferroptosis-Associated Pathways in Breast Cancer with Heterogeneous Prognostic Implications and Systemic Response to Cryoablation.International journal of molecular sciences · 2026Article
- Emerging Protein Targets in Triple-Negative Breast Cancer: Beyond Conventional Therapy.Cancers · 2026Review
- Serum fatty acid profiles across clinicopathologic heterogeneity in breast cancer: an exploratory study.Therapeutic advances in medical oncology · 2026Article
- Distribution characteristics and associated factors of dyslipidemia across clinical stages of breast cancer: a retrospective observational study.Frontiers in global women's health · 2026Article
- Lipid Metabolic Reprogramming in Breast Cancer: Mechanisms and Emerging Therapeutic Strategies.Breast cancer (Dove Medical Press) · 2026Review
- Gene Expression Profiles Modulated by Lipophilic Sea Buckthorn (Food science & nutrition · 2025Article
- Integrated Pan-Cancer Analysis and Experimental Verification of the Roles of Retinoid-Binding Proteins in Breast Cancer.Cancers · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-negative breast cancer (TNBC) is a subtype of breast cancer associated with poor prognosis and limited targeted treatment options. Lipid metabolism plays a pivotal role in the initiation, progression, and metastasis of TNBC by supporting cancer cell energy production, facilitating membrane biosynthesis, and regulating signal transduction. Dysregulation of lipid metabolism promotes tumor cell proliferation and contributes to processes such as epithelial-mesenchymal transition (EMT), angiogenesis, and immune evasion. Targeting lipid metabolism-such as inhibiting fatty acid synthase (FASN) and lipid metabolic byproducts-has emerged as a promising therapeutic strategy. The integration of multi-omics approaches and advanced imaging technologies can further elucidate the interactions between lipid metabolism and the tumor microenvironment, thereby supporting precision oncology. Future research should explore the role of lipid metabolism in distinct TNBC subtypes, optimize therapeutic strategies, and improve patient outcomes, particularly for those who are unresponsive to conventional treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.